// App-Quantinova.ai

4113 : Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).

Researchers

Presenter

  • Jaume Capdevila

Principal Investigators

  • Gabriela Jimenez-Valerio

  • Alba Martinez

  • Jorge Hernando

  • Toni Ibrahim

  • Nicola Fazio

  • Carlos Lopez

  • Alex Teule

  • Juan W. Valle

  • Salvatore Tafuto

  • Ana B. Custodio

  • Nicholas Simon Reed

  • Markus Raderer

  • Enrique Grande

  • Rocio Garcia-Carbonero

  • Paula Jimnez-Fonseca

  • Vicente Alonso

  • Oriol Casanovas

Medical Centers

  • Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology, Vall d’Hebron University Hospital (HUVH), Barcelona, Spain

  • Catalan Institute of Oncology, IDIBELL, Barcelona, Spain

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Osteoncology and Rare Tumors Center IRCCS Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori - IRST, Meldola, Italy

  • European Institute of Oncology, Milan, Italy

  • Marques de Valdecilla University Hospital, Santander, Spain

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • Hospital Universitario La Paz, Madrid, Spain

  • Gartnavel General Hospital, Glasgow, United Kingdom

  • Department of Medicine I, Medical University of Vienna, Austria

  • GEICO & MD Anderson Cancer Center Madrid, Madrid, Spain

  • Hospital Universitario 12 de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain

Locations

  • Spain

  • Italy

  • United Kingdom

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroenteropancreatic neuroendocrine carcinomas

Biomarkers

  • Fibroblast growth factor 2

  • C-Fos Induced Growth Factor

  • C-X-C motif chemokine ligand 8

  • Vascular endothelial growth factor A

  • Kinase Insert Domain Receptor

  • Vascular Endothelial Growth Factor C

Drug/Treatment

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved